Xenon to Present at Upcoming Investor Conferences

Rhea-AI Summary

Xenon Pharmaceuticals (Nasdaq: XENE) will present at two investor conferences in November 2025: the Stifel 2025 Healthcare Conference on Thursday, November 13, 2025 at 3:20 PM ET and the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025 at 11:30 AM GMT / 6:30 AM ET. Webcasts are mentioned and will be posted for replay when available. Dates and times are subject to change.

The release reiterates Xenon’s focus on neuroscience drug discovery and development, notes lead molecule azetukalner is in Phase 3 for epilepsy, MDD and BPD, and references Phase 1 programs for Nav1.7 and Kv7 targeting pain. Investor materials and webcast links will be available on Xenon’s Investors webpage.

VANCOUVER, British Columbia and BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the Company will present at two upcoming investor conferences.

• Stifel 2025 Healthcare Conference
  Thursday, November 13, 2025 at 3:20 PM ET
  Webcast link here

• Jefferies Global Healthcare Conference in London on
  Wednesday, November 19, 2025 at 11:30 AM GMT/6:30 AM ET
  Webcast link here

Details about company presentations, webcasts, and other events can be found on the Investors section of Xenon's website. When available, webcasts will be posted for replay following the event. The above-listed dates and times are subject to change.

About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Xenon’s lead molecule, azetukalner, is a novel, potent, selective Kv7 potassium channel opener in Phase 3 clinical studies for the treatment of epilepsy, major depressive disorder (MDD) and bipolar depression (BPD). Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including Nav1.7 and Kv7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts. For more information, visit www.xenon-pharma.com and follow us on LinkedIn and X.

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Contact:

Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
Media: media@xenon-pharma.com
Investors: investors@xenon-pharma.com

FAQ

When will Xenon (XENE) present at the Stifel 2025 Healthcare Conference?

Xenon will present on Thursday, November 13, 2025 at 3:20 PM ET.

When and where is Xenon (XENE) presenting at the Jefferies Global Healthcare Conference?

Xenon will present in London on Wednesday, November 19, 2025 at 11:30 AM GMT / 6:30 AM ET.

Will Xenon (XENE) provide webcasts of its November 2025 conference presentations?

Yes. Webcasts are planned and will be posted for replay on Xenon’s Investors webpage when available.

Where can investors find Xenon (XENE) presentation details and replays from November 2025?

Presentation details and webcast replays will be available in the Investors section of Xenon’s website.

What pipeline updates does Xenon (XENE) reference in the November 6, 2025 announcement?

The announcement notes lead molecule azetukalner is in Phase 3 for epilepsy, MDD and BPD and mentions Phase 1 Nav1.7 and Kv7 pain programs.